IPP Bureau
AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib
By IPP Bureau - August 23, 2025
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site
By IPP Bureau - August 22, 2025
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Fortis Healthcare signs O&M agreement with Ekana Group for 550-bed hospital in Lucknow
By IPP Bureau - August 22, 2025
The facility will be positioned as a Centre of Excellence for tertiary care services
Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr
By IPP Bureau - August 22, 2025
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
FDA lifts hold on Rocket Pharma's gene therapy trial
By IPP Bureau - August 22, 2025
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
By IPP Bureau - August 21, 2025
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India
By IPP Bureau - August 21, 2025
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
HGM acquires Aideo Technologies for Rs. 14 crore to strengthen AI-powered healthcare services platform
By IPP Bureau - August 21, 2025
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
By IPP Bureau - August 21, 2025
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders
By IPP Bureau - August 20, 2025
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Foxconn invests US$30 million in Robocore to expand into elderly care robotics market
By IPP Bureau - August 20, 2025
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial
By IPP Bureau - August 19, 2025
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair
By IPP Bureau - August 19, 2025
Alembic receives USFDA final approval for Macitentan Tablets, 10 mg
By IPP Bureau - August 19, 2025
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Novo Nordisk's Wegovy approved in the US for the treatment of MASH
By IPP Bureau - August 19, 2025
The accelerated approval is supported by results from part 1 of the ESSENCE trial
